Mcts - NutraPedia

Back to Table of Contents

Medium-Chain Triglycerides (MCTs) - Health Overview

1) Conditions Studied for MCTs

MCTs have been studied for a variety of conditions including:

  • Weight management and obesity
  • Alzheimer's disease and cognitive decline
  • Epilepsy
  • Diabetes
  • Athletic performance enhancement
  • Cardiovascular disease

2) Effectiveness in Treating Conditions

Research on the effectiveness of MCTs in treating the aforementioned conditions has yielded mixed results:

  • MCTs may promote weight loss by increasing energy expenditure and reducing appetite.
  • Some studies suggest MCTs can provide an alternative energy source for brain cells in Alzheimer's patients, potentially improving symptoms.
  • For epilepsy, MCTs are used as part of a ketogenic diet to help control seizures.
  • There is limited evidence on the effectiveness of MCTs in improving glycemic control in diabetics.
  • Athletes may benefit from MCTs for quick energy and enhanced endurance, though evidence is not conclusive.
  • The impact of MCTs on cardiovascular health is still under investigation, with some studies indicating potential benefits for lipid profiles.

3) Health Benefits of MCTs

MCTs are associated with several health benefits, such as:

  • Quick source of energy due to rapid metabolism
  • Potential weight loss aid by increasing satiety and thermogenesis
  • May improve cognitive function in certain neurological conditions
  • Support for a ketogenic dietary approach in epilepsy management

4) Downsides of MCTs

While MCTs are generally considered safe, there are some potential downsides:

  • High doses can lead to gastrointestinal discomfort, such as diarrhea and cramping.
  • Overconsumption can contribute to fat accumulation, given their caloric content.
  • MCTs may not be suitable for individuals with liver disease due to the liver's role in metabolizing fats.

5) MCTs and Genetic Variations

The interaction between MCTs and genetic variations is an emerging area of research. Some points to consider include:

  • Individuals with certain genetic mutations affecting fat metabolism may respond differently to MCT supplementation.
  • There is some suggestion that genetic variants related to fatty acid transport and metabolism could influence the efficacy of MCTs in weight management and energy production.
  • More research is needed to draw definitive conclusions about the benefits or risks of MCTs for specific genetic variations.

Research Summary on Medium Chain Triglycerides (MCTs)

The absorption of medium chain triglycerides (MCTs), particularly lauric and octanoic acids, through the lymphatic system has been shown to be notable, although it varies between different MCTs. MCTs are not preferentially absorbed directly into the portal vein, suggesting involvement of the lymphatic system to some extent.

Medical and Nutritional Uses of MCTs

MCTs have been utilized in treating malabsorption and hyperlipidemia. They have applications in medical nutrition therapy, including hyperalimentation, carnitine deficiency, epilepsy, and obesity. The metabolism of MCTs occurs in the liver and other tissues.

MCTs and Dietary Fat Absorption

Understanding dietary fat absorption is crucial in the context of the obesity epidemic. MCTs affect the secretion of digestive hormones like cholecystokinin (CCK) and influence human gastric motility. They also impact the secretion of pancreatic enzymes and gallbladder function differently from long-chain triglycerides (LCTs).

Impact of MCTs on Fatty Acid Composition

Different dietary fats, including MCTs, LCTs, and structured lipids, directly influence the fatty acid composition of the intestine and the absorption process in the lymphatic system and portal vein.

Research Findings on MCT Supplementation

  • MCT consumption may lead to a reduction in food intake and aid in weight control.
  • When ingested with beta-carotene, MCTs decrease its bioavailability.
  • MCTs, as part of a high-fat diet, can lead to significant incorporation of medium-chain fatty acids into chylomicron triglycerides.
  • MCTs may not stimulate the secretion of pancreatic enzymes or gallbladder contraction like LCTs do.

Considerations for MCT Use in Treatment

Further studies are needed to understand the implications of MCT supplementation in the treatment of conditions such as chylous leaks and to explore the factors influencing the absorption of fatty acids of different chain lengths in both healthy and pathological states.

Conclusions

The reviewed research suggests that while MCTs have several health and nutritional benefits, their absorption patterns and effects on the body's metabolism are complex and may differ from long-chain fatty acids. This warrants additional research to fully comprehend their role in medical and nutritional contexts.

References:


  1. Lymphatic absorption of glucose and fatty acids as determined by direct measurement
  2. Determination of the route of medium-chain and long-chain fatty acid absorption by direct measurement in the rat
  3. Medium-chain triglycerides: an update
  4. The metabolism of structured triacylglycerols
  5. Development and physiological regulation of intestinal lipid absorption. II. Dietary lipid absorption, complex lipid synthesis, and the intracellular packaging and secretion of chylomicrons
  6. Fatty acid chain length determines cholecystokinin secretion and effect on human gastric motility
  7. The effect of equicaloric medium-chain and long-chain triglycerides on pancreas enzyme secretion
  8. Effects of medium-chain triglycerides, long-chain triglycerides, or 2-monododecanoin on fatty acid composition in the portal vein, intestinal lymph, and systemic circulation in rats
  9. Relative rates of metabolism MCT, LCT and ethanol in man
  10. Chylomicron beta-carotene and retinyl palmitate responses are dramatically diminished when men ingest beta-carotene with medium-chain rather than long-chain triglycerides
  11. Medium-chain fatty acids: evidence for incorporation into chylomicron triglycerides in humans
  12. Carnitine-acylcarnitine translocase deficiency, clinical, biochemical and genetic aspects
  13. Effect of the fatty acid composition of ingested fats on rat liver intermediary metabolism
  14. Oxaloacetate deficiency in MCT-induced ketogenesis
  15. Regulation of hepatic fatty acid oxidation and ketone body production
  16. Relation of ketosis to metabolic changes induced by acute medium-chain triglyceride feeding in rats
  17. Ketogenic response to medium-chain triglyceride load in the rat
  18. The regulation of ketogenesis from octanoic acid. The role of the tricarboxylic acid cycle and fatty acid synthesis
  19. Uptake of valproic acid into rat brain is mediated by a medium-chain fatty acid transporter
  20. Seizure control by decanoic acid through direct AMPA receptor inhibition
  21. Substrate oxidation and control of food intake in men after a fat-substitute meal compared with meals supplemented with an isoenergetic load of carbohydrate, long-chain triacylglycerols, or medium-chain triacylglycerols
  22. Food intake in dieters and nondieters after a liquid meal containing medium-chain triglycerides
  23. Impact of medium and long chain triglycerides consumption on appetite and food intake in overweight men
  24. Influence of medium-chain and long-chain triacylglycerols on the control of food intake in men
  25. Covert manipulation of the ratio of medium- to long-chain triglycerides in isoenergetically dense diets: effect on food intake in ad libitum feeding men
  26. Value of VLCD supplementation with medium chain triglycerides
  27. Effects of dietary medium-chain triglyceride on weight loss and insulin sensitivity in a group of moderately overweight free-living type 2 diabetic Chinese subjects
  28. Ketogenic diet and other dietary treatments for epilepsy
  29. Neurobiochemical mechanisms of a ketogenic diet in refractory epilepsy
  30. Mechanisms of Ketogenic Diet Action
  31. Long-term impact of the ketogenic diet on growth and resting energy expenditure in children with intractable epilepsy
  32. Progressive bone mineral content loss in children with intractable epilepsy treated with the ketogenic diet
  33. Medium-chain triglycerides as a therapy for intractable childhood epilepsy
  34. Ketonemia and seizures: metabolic and anticonvulsant effects of two ketogenic diets in childhood epilepsy
  35. Medium-chain triglyceride (MCT) diet in intractable seizure disorders
  36. The medium chain triglyceride diet and intractable epilepsy
  37. Ketogenic diets in the treatment of epilepsy: short-term clinical effects
  38. Metabolic effects of three ketogenic diets in the treatment of severe epilepsy
  39. Medium-chain triglyceride (MCT) ketogenic therapy
  40. Medium-chain triglyceride ketogenic diet, an effective treatment for drug-resistant epilepsy and a comparison with other ketogenic diets
  41. Growth of children on classical and medium-chain triglyceride ketogenic diets
  42. A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treatment of childhood epilepsy
  43. Marked Seizure Reduction after MCT Supplementation
  44. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults
  45. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial
  46. Pilot feasibility and safety study examining the effect of medium chain triglyceride supplementation in subjects with mild cognitive impairment: A randomized controlled trial
  47. Can Ketones Help Rescue Brain Fuel Supply in Later Life? Implications for Cognitive Health during Aging and the Treatment of Alzheimer's Disease
  48. Dietary medium-chain triacylglycerols suppress accumulation of body fat in a double-blind, controlled trial in healthy men and women
  49. Mechanisms mediating lipoprotein responses to diets with medium-chain triglyceride and lauric acid
  50. Effects of medium chain fatty acids (MCFA), myristic acid, and oleic acid on serum lipoproteins in healthy subjects
  51. Plasma lipids and lipoproteins during 6 d of maintenance feeding with long-chain, medium-chain, and mixed-chain triglycerides
  52. Changes in blood lipids during six days of overfeeding with medium or long chain triglycerides
  53. Effect of a saturated medium-chain triglyceride on serum-lipids in man
  54. Medium chain triglyceride oil consumption as part of a weight loss diet does not lead to an adverse metabolic profile when compared to olive oil
  55. Dietary medium-chain triglyceride supplementation has no effect on apolipoprotein B-48 and apolipoprotein B-100 kinetics in insulin-resistant men
  56. Dietary medium chain fatty acid supplementation leads to reduced VLDL lipolysis and uptake rates in comparison to linoleic acid supplementation
  57. Effect of high fat weanling diets containing either medium-chain triglycerides or long-chain triglycerides on the development of obesity in the Zucker rat
  58. Effect of dietary medium- and long-chain triacylglycerols (MLCT) on accumulation of body fat in healthy humans
  59. Consumption of medium- and long-chain triacylglycerols decreases body fat and blood triglyceride in Chinese hypertriglyceridemic subjects
  60. [Medium- and long-chain fatty acid triacylglycerol reduce body fat and serum triglyceride in overweight and hypertriglyceridemic subjects]
  61. A good response to oil with medium- and long-chain fatty acids in body fat and blood lipid profiles of male hypertriglyceridemic subjects
  62. Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture
  63. Medium- and long-chain triacylglycerols reduce body fat and blood triacylglycerols in hypertriacylglycerolemic, overweight but not obese, Chinese individuals
  64. Dietary medium-chain triacylglycerol prevents the postprandial rise of plasma triacylglycerols but induces hypercholesterolemia in primary hypertriglyceridemic subjects
  65. Comparison of the effects of medium-chain triacylglycerols, palm oil, and high oleic acid sunflower oil on plasma triacylglycerol fatty acids and lipid and lipoprotein concentrations in humans
  66. HYPERGLYCERIDEMIA RESULTING FROM INTAKE OF MEDIUM CHAIN TRIGLYCERIDES
  67. Dietary substitution of medium-chain triglycerides improves insulin-mediated glucose metabolism in NIDDM subjects
  68. A Diet Rich in Medium-Chain Fatty Acids Improves Systolic Function and Alters the Lipidomic Profile in Patients With Type 2 Diabetes: A Pilot Study
  69. Medium-chain triacylglycerols may not raise cholesterol
  70. Insulin and ketone responses to ingestion of medium and long-chain triglycerides in man
  71. Effects of a single oral load of medium-chain triglyceride on serum lipid and insulin levels in man
  72. Dietary substitution of medium chain triglycerides in subjects with non-insulin-dependent diabetes mellitus in an ambulatory setting: impact on glycemic control and insulin-mediated glucose metabolism
  73. Effects of feeding medium-chain triacylglycerols on maternal lipid metabolism and pup growth in lactating rats
  74. Difference in hepatic metabolism of long- and medium-chain fatty acids: the role of fatty acid chain length in the production of the alcoholic fatty liver
  75. Medium-chain-triglyceride lipid emulsion: metabolism and tissue distribution
  76. Diagnosis and differentiation of fat malabsorption in children using 13C-labeled lipids: trioctanoin, triolein, and palmitic acid breath tests
  77. Medium- and long-chain triglycerides labeled with 13C: a comparison of oxidation after oral or parenteral administration in humans
  78. 13C abundances of nutrients and the effect of variations in 13C isotopic abundances of test meals formulated for 13CO2 breath tests
  79. Endogenous fat oxidation during medium chain versus long chain triglyceride feeding in healthy women
  80. Influence of human obesity on the metabolic fate of dietary long- and medium-chain triacylglycerols
  81. Carnitine Palmitoyltransferase 1A Deficiency
  82. Overfeeding with medium-chain triglyceride diet results in diminished deposition of fat
  83. Differential effects of high-fat diets varying in fatty acid composition on the efficiency of lean and fat tissue deposition during weight recovery after low food intake
  84. Metabolic effects induced by long-term feeding of medium-chain triglycerides in the rat
  85. Effect of medium chain triglyceride on lipogenesis and body fat in the rat
  86. Components of total energy expenditure in healthy young women are not affected after 14 days of feeding with medium-versus long-chain triglycerides
  87. Value of VLCD supplementation with medium chain triglycerides
  88. Structured medium and long chain triglycerides show short-term increases in fat oxidation, but no changes in adiposity in men
  89. Effects of dietary coconut oil on the biochemical and anthropometric profiles of women presenting abdominal obesity
  90. Effect of dietary medium- and long-chain triacylglycerols (MLCT) on accumulation of body fat in healthy humans
  91. Dietary medium-chain triacylglycerols suppress accumulation of body fat in a double-blind, controlled trial in healthy men and women
  92. Effects of dietary medium-chain triglyceride on weight loss and insulin sensitivity in a group of moderately overweight free-living type 2 diabetic Chinese subjects
  93. Medium-chain triglycerides are advantageous in promoting weight loss although not beneficial to exercise performance
  94. Strategies to enhance fat utilisation during exercise
  95. Preexercise medium-chain triglyceride ingestion does not alter muscle glycogen use during exercise
  96. Chronic medium-chain triacylglycerol consumption and endurance performance in trained runners
  97. The effects of medium-chain triacylglycerol and carbohydrate ingestion on ultra-endurance exercise performance
  98. Effect of carbohydrate or carbohydrate plus medium-chain triglyceride ingestion on cycling time trial performance
  99. The effect of medium-chain triglyceride on 47 calcium absorption in patients with primary biliary cirrhosis
  100. Effect of medium chain triglyceride on fecal calcium losses in pancreatic insufficiency
  101. The effects of medium-chain triglycerides in the short bowel syndrome. Increased glucose and water transport
  102. Review of the toxicologic properties of medium-chain triglycerides
  103. A simple practice guide for dose conversion between animals and human


Upload Whole Genome Sequencing (WGS) raw DNA data today and take a deep dive into your genome!

Or if you only have standard microarray data currently, upload raw DNA data to get started with your free DNA raw data analysis today!